Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Legend Capital

Founders Nengguang Wang

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 489
Average round size
info
The average size of a deal this fund participated in
$48M
Portfolio companies 353
Rounds per year 21.26
Lead investments 139
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.28
Exits 34
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Health Care
  • Medical
  • Biotechnology
  • Manufacturing
  • Medical Device
Summary

Legend Capital appeared to be the VC, which was created in 2001. The venture was found in Asia in China. The main office of represented VC is situated in the Beijing.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Legend Capital, startups are often financed by Qiming Venture Partners, Matrix Partners China, IDG Capital. The meaningful sponsors for the fund in investment in the same round are GGV Capital, Sequoia Capital China, SIG China (SIG Asia Investments). In the next rounds fund is usually obtained by GGV Capital, Tencent Holdings, Sequoia Capital China.

Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Beijing LaKala Billing Services, Renren Inc., Ucar We can highlight the next thriving fund investment areas, such as Information Technology, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little.

The overall number of key employees were 8.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The typical startup value when the investment from Legend Capital is 500 millions - 1 billion dollars. The fund is constantly included in 7-12 investment rounds annually. The top amount of exits for fund were in 2018. Comparing to the other companies, this Legend Capital performs on 19 percentage points less the average number of lead investments. The real fund results show that this VC is 27 percentage points more often commits exit comparing to other companies.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Legend Capital:
Typical Co-investors
Legend Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Legend Capital:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

MacroLux

Health Care
Medical
23 Oct 2024 Shenzhen, Guangdong, China

Ruicycle

Battery
24 Aug 2024 Futian, Guangdong, China

Ensurge Medical

Health Care
Medical
Medical Device
$15M19 Aug 2024 Suzhou, Jiangsu, China

Xellar Biosystems

Biotechnology
Pharmaceutical
$15M17 Jul 2024 Newton, Massachusetts, United States

Volant Aerotech

Aerospace
Air Transportation
Industrial
Manufacturing
$15M05 Jul 2024 -

Zhongke Guosheng

Advanced Materials
Chemical
Chemical Engineering
Manufacturing
$15M12 Mar 2024 Hangzhou, Zhejiang, China

Dearer Medical

Eyewear
Medical
Medical Device
22 Jan 2024 Minhang, Shanghai, China

MacroLux

Health Care
Medical
15 Jan 2024 Shenzhen, Guangdong, China

Leapstack

Artificial Intelligence
Big Data
Financial Services
Health Insurance
Insurance
InsurTech
Machine Learning
$30M29 Dec 2023 Shanghai, China
News
Lynk Pharmaceuticals Closes $50M Series B Financing

– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.

Berry Oncology Closes US$99.15M Series B1 Funding

– Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round.
– This round was led by China Merchants Capital Management Co., Ltd. Existing investors Qiming Venture Partners and Legend Capital, along with new investors including Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management Co., Ltd., Xiamen C&D Emerging Industry Equity Investment Co., Ltd. and other investors also participated.
– The new proceeds will enable the company to meet the demand for early cancer screening and diagnosis and boost its expansion in the market.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Legend Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 489
Average round size 48M
Rounds per year 21.26
Peak activity year 2018
Lead investments 139
Follow on index 0.28
Exits 34
Group Appearance index 0.79

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

MacroLux

Health Care
Medical
23 Oct 2024 Shenzhen, Guangdong, China

Ruicycle

Battery
24 Aug 2024 Futian, Guangdong, China

Ensurge Medical

Health Care
Medical
Medical Device
$15M19 Aug 2024 Suzhou, Jiangsu, China

Xellar Biosystems

Biotechnology
Pharmaceutical
$15M17 Jul 2024 Newton, Massachusetts, United States

Volant Aerotech

Aerospace
Air Transportation
Industrial
Manufacturing
$15M05 Jul 2024 -

Zhongke Guosheng

Advanced Materials
Chemical
Chemical Engineering
Manufacturing
$15M12 Mar 2024 Hangzhou, Zhejiang, China

Dearer Medical

Eyewear
Medical
Medical Device
22 Jan 2024 Minhang, Shanghai, China

MacroLux

Health Care
Medical
15 Jan 2024 Shenzhen, Guangdong, China

Leapstack

Artificial Intelligence
Big Data
Financial Services
Health Insurance
Insurance
InsurTech
Machine Learning
$30M29 Dec 2023 Shanghai, China
Crunchbase icon

Content report

The following text will be sent to our editors: